1. Academic Validation
  2. Nanoparticle-modified chitosan-agarose-gelatin scaffold for sustained release of SDF-1 and BMP-2

Nanoparticle-modified chitosan-agarose-gelatin scaffold for sustained release of SDF-1 and BMP-2

  • Int J Nanomedicine. 2018 Nov 12;13:7395-7408. doi: 10.2147/IJN.S180859.
Bin Wang 1 Yuanwei Guo 2 Xiaofeng Chen 3 Chao Zeng 1 Qikang Hu 1 Wei Yin 1 Wei Li 1 Hui Xie 1 Bingyu Zhang 1 Xingchun Huang 1 Fenglei Yu 1
Affiliations

Affiliations

  • 1 Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha 410011, People's Republic of China, yufenglei@csu.edu.cn.
  • 2 Center for Clinical Pathology, Affiliated to The First People's Hospital of Chenzhou, University of South China, Chenzhou 432000, People's Republic of China.
  • 3 Department of Anesthesiology, The Second Xiangya Hospital of Central South University, Changsha 410011, People's Republic of China.
Abstract

Background: Stromal cell-derived factor 1 (SDF-1) is an important chemokine for stem cell mobilization, and plays a critical role in mobilization of mesenchymal stem cells (MSCs). Bone Morphogenetic Protein 2 (BMP-2) plays a critical role in osteogenesis of MSCs. However, the use of SDF-1 and BMP-2 in bone tissue engineering is limited by their short half-lives and rapid degradation in vitro and in vivo.

Methods: The chitosan oligosaccharide/heparin nanoparticles (CSO/H NPs) were first prepared via self-assembly. Chitosan-agarose-gelatin (CAG) Scaffolds were then synthesized via gelation technology using cross-linked chitosan, Agarose, and gelatin, and were modified by CSO/H NPs. The encapsulation efficiency and release kinetics of SDF-1 and BMP-2 were quantified using an enzyme-linked immunosorbent assay. A CCK-8 assays were used to evaluate biocompatibility of NP-modified scaffolds. The biological activity of the loaded SDF-1 and BMP-2 was evaluated using the transwell migration assay and osteogenic induction assay. An animal MSC recruitment model was used to study the ability of SDF-1 released from NP-modified scaffolds to induce migration of MSCs.

Results: In this study, we developed a novel nanoparticle-modified CAG scaffold for the delivery of SDF-1 and BMP-2. CCK-8 assays demonstrated excellent biocompatibility of NP-modified scaffolds. In addition, we investigated the release of SDF-1 and BMP-2 from NP-modified scaffolds, and evaluated the effect of released SDF-1 on MSC migration. The effect of released BMP-2 on MSC osteogenesis was also examined. In vitro cell migration assays showed that SDF-1 released from NP-modified scaffolds retained its migration activity; osteogenesis studies demonstrated that released BMP-2 exhibited a strong ability to induce differentiation towards osteoblasts. Our in vivo recruitment assays showed continuous chemotactic response of MSCs to SDF-1 released from the NP-modified scaffold.

Conclusion: The simplicity of synthesizing CSO/H NP-modified CAG scaffolds, combined with its high cytokine loading capacity and sustained release effect, renders NP-modified CAG scaffold an attractive candidate for sustained release of SDF-1 and BMP-2 to promote bone repair and regeneration.

Keywords

bone morphogenetic protein-2; chitosan-agarose-gelatin scaffold; cytokine delivery system; nanoparticles; stromal cell-derived factor-1.

Figures
Products